CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit organization dedicated to building a stakeholder-driven integrated global system for clinical research, announced a strategic partnership.
CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), a multi-sector non-profit organization dedicated to building a stakeholder-driven integrated global system for clinical research, announced a strategic partnership. The agreement will bring CluePoints into the ‘ACRES Alliance', a growing collaborative of excellence-minded, innovation-focused organizations from across the global clinical research enterprise, and will focus on improving data quality in clinical research by identifying potential risks at investigative sites.
The collaboration will initially explore opportunities for streamlining and improving the effectiveness of on-site monitoring visits by bringing CluePoints' CSM solutions to the ACRES shared global platform of integrated technologies, with the goal of improving the integrity of data and reducing trial costs. CluePoints and ACRES will also explore the potential of building the CSM solution into ACRES' global system to identify operational and performance problems in a trial before they actually happen, using historical databases of data quality and performance indicators from selected investigative sites. In addition, CluePoints will participate in ACRES' Foundation Initiatives related to quality management, site accreditation and standards, contributing to the “dynamic accreditation” process being developed by the Alliance.
Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.